{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:17:44Z","timestamp":1778944664673,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cllc.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T19:33:12Z","timestamp":1750447992000},"page":"595-602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Case of Retroperitoneal Fibrosis During Antiprogrammed Cell Death 1 Antibody Treatment"],"prefix":"10.1016","volume":"26","author":[{"given":"C.","family":"Kouroussis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Thanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tsipoura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Koulaxouzidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Chaniotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2025.06.008_bib0001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.berh.2012.07.004","article-title":"Retroperitoneal fibrosis","volume":"26","author":"Pipitone","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.cllc.2025.06.008_bib0002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/tre.949","article-title":"IgG4-related retroperitoneal fibrosis needs comprehensive treatment and regular long-term review","volume":"15","author":"Clark","year":"2024","journal-title":"Trend Urol Men\u2019s Health"},{"issue":"4","key":"10.1016\/j.cllc.2025.06.008_bib0003","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MD.0b013e3181afc420","article-title":"Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation","volume":"88","author":"van Bommel","year":"2009","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.cllc.2025.06.008_bib0004","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/MD.0b013e3181afc439","article-title":"Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation","volume":"88","author":"Scheel","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cllc.2025.06.008_bib0005","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-16-0664","article-title":"FDA approval summary: Pembrolizumab for the treatment of patients with unresectable or metastatic melanoma","volume":"23","author":"Barone","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2025.06.008_bib0006","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.1158\/1078-0432.CCR-22-1110","article-title":"FDA approval summary: Pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer","volume":"28","author":"Shah","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2025.06.008_bib0007","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40273-018-0752-0","article-title":"Q-TWiST analysis to assess benefit-risk of Pembrolizumab in patients with PD-L1-positive advanced or metastatic non-small cell lung cancer","volume":"37","author":"Huang","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.cllc.2025.06.008_bib0008","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.06.008_bib0009","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/21691401.2022.2131354","article-title":"Treatment-related adverse events of PD-1\/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis","volume":"50","author":"Mi","year":"2022","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1016\/j.cllc.2025.06.008_bib0010","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus Pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.06.008_bib0011","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1158\/2326-6066.CIR-18-0086","article-title":"Stromal fibroblasts mediate Anti\u2013PD-1 resistance via MMP-9 and dictate tgf\u03b2 inhibitor sequencing in melanoma","volume":"6","author":"Zhao","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.cllc.2025.06.008_bib0012","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.2482\/haigan.62.1044","article-title":"Two cases of retroperitoneal fibrosis during anti-programmed cell death 1 antibody treatment","volume":"62","author":"Fujiu","year":"2022","journal-title":"Haigan"},{"key":"10.1016\/j.cllc.2025.06.008_bib0013","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/1759-7714.15155","article-title":"IgG4-related retroperitoneal fibrosis induced by nivolumab and ipilimumab in a patient with non-small cell lung cancer: A case report","volume":"15","author":"Nishimura","year":"2024","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2025.06.008_bib0014","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1093\/rheumatology\/keab264","article-title":"Anti-PD-1 associated retroperitoneal fibrosis","volume":"60","author":"Daoussis","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cllc.2025.06.008_bib0015","article-title":"Case report: A programmed cell death-1 inhibitor-related abdominal fibroinflammatory reaction affecting multiple organs in A non-small-cell lung cancer patient","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"issue":"9506","key":"10.1016\/j.cllc.2025.06.008_bib0016","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(06)68035-5","article-title":"Retroperitoneal fibrosis","volume":"367","author":"Vaglio","year":"2006","journal-title":"Lancet"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042500141X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042500141X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:02:33Z","timestamp":1778943753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573042500141X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S152573042500141X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.06.008","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Case of Retroperitoneal Fibrosis During Antiprogrammed Cell Death 1 Antibody Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}